Eli Lilly partners with OpenAI for drug discovery using generative AI, showing promise for growth.

From NASDAQ.: 2024-06-29 06:15:00

Eli Lilly, a top pharmaceutical company, is making waves in the weight loss market with its blockbuster drugs, Mounjaro and Zepbound. The FDA endorsed Lilly’s Alzheimer’s candidate, donanemab, boosting the company’s profile. Now, Lilly is partnering with OpenAI in drug discovery, utilizing generative AI in healthcare.

AI has vast potential in healthcare, with the market projected to reach $187 billion by 2030. Novo Nordisk is also leveraging AI with a supercomputer powered by Nvidia. Lilly’s collaboration with OpenAI aims to develop novel antimicrobials to combat drug-resistant pathogens, addressing a critical global health concern.

The partnership with OpenAI has caused a 2% increase in Lilly’s stock. While this alone doesn’t make it a buy, it signals progress in future endeavors with potential in weight loss, cancer, Alzheimer’s treatment, and now antimicrobial resistance research. If Lilly makes headway in AMR, it could lead to more AI applications and partnerships, positioning the company for growth.

For investors considering Eli Lilly, Stock Advisor advises on the 10 best stocks, excluding Lilly. Past picks like Nvidia have seen significant returns. While speculative, Lilly’s collaboration with OpenAI could lead to promising developments. Monitoring Lilly’s progress and strategic approach to AI could provide valuable insights for investors.



Read more at NASDAQ.: Eli Lilly Is Teaming Up With OpenAI. Here Are 3 Things Smart Investors Should Know.